RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study (Q98665514)
Jump to navigation
Jump to search
scientific article published on 20 August 2020
Language | Label | Description | Also known as |
---|---|---|---|
English | RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study |
scientific article published on 20 August 2020 |
Statements
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study (English)
Vanessa Raabe
Kirsten E Lyke
Camila Fontes-Garfias
Özlem Türeci
Philip R Dormitzer
Warren Kalina
Mark J Mulligan
William C Gruber
Kathrin U Jansen
Kathleen Neuzil
David Cooper
Pei-Yong Shi
Robert Frenck
Ann R Falsey
Kena A Swanson
Alejandra Gurtman
Nicholas Kitchin
Judith Absalon
Stephen Lockhart
Edward E Walsh
Ruth Bailey
Ping Li
Kristin R Thompkins